Table 1 Studies reporting on the persistence of immunogenicity following primary vaccination with a single dose of a MCV4 vaccine.
Study assessing the primary dose | Country | Age at primary dose | Vaccines used as primary dose | Study assessing antibody persistence | Study design | Time between primary dose and antibody persistence assessment |
|---|---|---|---|---|---|---|
Vesikari et al. (NCT00427908)25 March 2015 to August 2015 | Finland | Toddlers: 12–23 months | MenACYW-TT (MenQuadfi®) MCV4-TT (Nimenrix®) | Piazza et al. (NCT03476135)22 February 2018 to September 2018 | Phase 3, randomized, modified double-blind, immune-persistence and booster study in children | 3 years |
van der Vliet et al. (NCT02955797)35 February 2017 to October 2017 | Finland, Germany, Hungary, and Spain | Toddlers: 12–23 months | MenACYW-TT (MenQuadfi®) | Martinón-Torres et al. (NCT04936685)34 August 2022 to February 2023 | Phase 3b, open-label, multi-center study in children | 5 years |
Dhingra et al. (NCT02842853)28 July 2016 to February 2017 Chang et al. (NCT02199691)27 July 2014 to October 2015 | USA and Puerto Rico | Naïve adolescents/young adults : ≥ 13 to < 26 years | MenACYW-TT (MenQuadfi®) MenACWY-CRM (Menveo®) | Zambrano et al.26 (NCT04084769) September 2019 to September 2020 | Phase 3b randomized, modified double-blind, immune-persistence and booster study in adolescents and adults | 3–6 years |
Esteves-Jarmillo et al. (NCT02842866)32 July 2016 to February 2017 Kirstien et al. (NCT01732627)33 November 2012 to January 2013 | USA and Puerto Rico | Naïve older adults: ≥ 56 years | MenACYW-TT (MenQuadfi®) MPSV4 (Menomune®) MenACYW-TT (MenQuadfi®) MPSV4 (Menomune®) | Robertson et al. (NCT04142242)29,30 October 2019 to April 2020 | Phase 3, randomized, open-label, immune-persistence and booster study in older adults | 3 years 5 years 6–7 years |
